Navigation Links
QRxPharma Initiates Second Phase III Clinical Trial for its 'Dual Opioid' Pain Therapy
Date:12/13/2007

Safety extension study to be part of NDA submission in 2009

SYDNEY, Australia, Dec. 13 /PRNewswire/ -- QRxPharma (ASX: QRX) announced today the initiation of a second Phase III clinical trial for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy. This placebo controlled, double blind safety extension trial is designed to collect longer-term use patient safety data in support of the Company's submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the use of Q8003IR in the management of moderate to severe pain.

"The initiation of QRxPharma's second Phase III study is part of our planned series of clinical trials leading to submission of our NDA for Q8003IR in 2009, with product launch anticipated in 2010," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "This safety extension study follows the commencement of the Company's first Phase III study for acute post-surgical pain announced on November 26, 2007."

For this Phase III safety extension trial, patients actively enrolled in the post-surgical bunionectomy trial have the option to continue receiving doses of Q8003IR to control pain for up to 28 additional days. Given the availability of this patient population, QRxPharma has elected to start this safety extension trial at this time, which corresponds with the timeline outlined in the Company's Prospectus. The precise number of patients needed, the dose levels achieved, and the duration of treatment required to complete the full longer-term use safety database for Q8003IR will be determined with the FDA. The primary end point of this safety extension trial is to evaluate the overall safety and side effect profile of Q8003IR when used for up to 28 days of treatment, followed by a withdrawal period of up to 3 weeks during which dosing with Q8003IR is gradually reduced.

Q8003IR is a patent-protected combination of two well-known
'/>"/>

SOURCE QRxPharma
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , WASHINGTON, Dec. 1 /PRNewswire-USNewswire...CDHPs) are more likely than those with traditional...haviors, to be more engaged in wellness programs, ...centives matter in holding down costs, according t... Employee Benefit Research Institute (EBRI). ,...
(Date:12/1/2009)... , FORT LAUDERDALE, Fla., Dec. 1 /PRNewswir... patient enrollment in the randomized clinical tri...tent (Combo Stent). ,, A prospective, randomize... valuation of an ablu M inal sirolimus coat ED ...tients at up to 20 sites in Asia, Australia, Europ...
(Date:12/1/2009)...insured patients in California are unable to succe...al care at hospitals despite recent state legislat...ing to a new study. , Posing as low-income unins...s from less than one-third of the hospitals they a...ch higher than those allowed under California law,...
(Date:12/1/2009)... Lumension announces general ...curity Suite to deliver end-to-end endpoint manage... and single management console architecture. , ...ber 1, 2009 -- Lumension, a global leader in endpo...w Lumension® Endpoint Management and Security...
(Date:12/1/2009)... , MILWAUKEE, Dec. 1 /PRNewsw...test asset is the ability to earn an income. It is...ssible to not only pay today,s mortgage but also t...ent costs. ,, Yet, according to a Northweste...21 and over have taken measures to protect their i...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 3
... More than 100 local VIPS,physicians and medical ...,Centers of America (DCA) Delray Beach medical fac...ionary breakthrough in cardiac and diagnostic,medi...yor Rita Ellis cut the ribbon at the medical "open...
...al Partners Purchase Interest from American ... BEND, Ind. and NEW YORK, Jan. 30 Press Ganey,Ass... performance,improvement solutions, announced toda...Partners, LLC (ASCP). The,Press Ganey management t...
... Expanding the,pipeline of HIV prevention tools i...icrobicides (IPM) today announced that Pfizer Inc....cense to maraviroc, its,newly-approved HIV treatme...iretroviral drugs known as CCR5 blockers, which,wo...
...e Michigan Chamber of,Commerce today released the ...alth Policy and Human Resources for the Michigan C... her State of the State address for the Michigan,S...,to move Michigan forward, we are disappointed tha...
..., especially those with genetic variant, study say... Exposure to secondhand smoke worsens lung functio...those with certain genetic variations, say U.S. re...smoke exposure, substantial numbers of individuals...
..., 2008) -- A new study from the Monell Center incr...esponsible for the nausea and vomiting that often ...ings could lead to the development of new approach... we move closer to providing patients with less tr...
Other Medicine News:Health News:Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with World's Most Advanced Cardiac Scanner. 2Health News:Press Ganey Takes on New Investment Partner 2Health News:Press Ganey Takes on New Investment Partner 3Health News:Press Ganey Takes on New Investment Partner 4Health News:IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide 2Health News:IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide 3Health News:Secondhand Smoke Worsens Lung Function in Cystic Fibrosis Patients 2Health News:Explaining chemotherapy-associated nausea 2
(Date:12/1/2009)...wire/ -- At this year,s annual meeting of the Radi...ilips Electronics ( PHG, AEX: PHI) will introduce ...that provides radiologists the ability to review m...p drive quality and efficiency. Showcasing its co...ht new capabilities for its portfolio of diagnosti...
(Date:12/1/2009)...ire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (...ntly completed preclinical study has affirmed the ...and Taxotere® (docetaxel). Shin Poong Pharma... Korea, independently conducted the study and data...f the bioequivalence and comparable overall safety...
(Date:12/1/2009)...ec. 1 Codexis, Inc. today announce... of its second agreement this year with Teva Pharm...eric drug manufacturer. The new agreement covers ...s announced an earlier agreement with Teva on Janu...e Codexis biocatalysis technology for key process ...
Breaking Medicine Technology:Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Codexis Expands Collaboration with Teva 2Addus HomeCare Corporation Prices Initial Public Offering 60201 1Addus HomeCare Corporation Prices Initial Public Offering 60201 2Adding Chemo Helps Head Neck Cancer Patients 60198 1Adding Chemo Helps Head Neck Cancer Patients 60198 2Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents According to Scientists at the Feinstein Institute for Medical Re 60196 1Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents According to Scientists at the Feinstein Institute for Medical Re 60196 2Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents According to Scientists at the Feinstein Institute for Medical Re 60196 3Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents According to Scientists at the Feinstein Institute for Medical Re 60196 4Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents According to Scientists at the Feinstein Institute for Medical Re 60196 5
... Researchers are,identifying innovative therapeut...factors in the disease,s progression, such as the .... According to a study prepublished,online in Bloo...,Hematology, a novel small molecule therapy called...n of red blood cells and increasing hemoglobin,lev...
...5 New polymer material designed to,stop bone blee...tion,according to a new animal study to be publish...dics and Related Research (CORR). The study has,im...red infections,including MRSA., Researchers from ...ston,and Keck School of Medicine at the University...
Other Medicine Technology:Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells 2Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells 3Ceremed's OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds 2Ceremed's OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds 3
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: